Oxford Biomedica Share Discussion Threads

[plutonian] 23/9/2022 09:21

Re #3927



concludes...

"This is our vaccine story...
...and we're not done yet"

Reference to imminent Serum Institute work?

[javascript] 23/9/2022 09:04

£118.5 million + £55 million - $85 million + breakeven = insolvency?

[javascript] 23/9/2022 08:56

copied from H1 results

Cash at 30 June 2022 was £118.5 million

The Group is in the process of part-repaying and refinancing the $85 million Oaktree loan facility taken out in March 2022 and a process is underway for the sale and leaseback of the Group’s Windrush Court facility in Oxford

The Group expects similar levels of revenues in the second half of 2022 as those achieved in the first half of 2022 and is expecting to deliver broadly break-even Operating EBITDA for the second half of the year

[mint1111] 23/9/2022 08:43

Cummings #3929You still talk as if OXB could be at the forefront of something special....They are.....it's called insolvency.....

[badger60] 23/9/2022 08:21

seanje.....what, you mean follow your investment picks? .....I suppose that OXB and OBD are at the top of your list......

[seanje] 23/9/2022 08:08

It must be very difficult for you Bodger all the money you have lost on your poor investment decisions. You need to spread your risks more.

[glavey] 23/9/2022 05:39

[3916] the 'grey', FWIW:

"Rather than working to move into new markets, as Nanopore is, Biomedica is looking to new or expanded customer partnerships to shore itself up after the pandemic, which was a boon given its vaccine partnership with AstraZeneca. It has signed five such agreements in the year to date, though analysts have warned that it could take time for these to improve profitability.

“More late clinical stage or commercial manufacturing partnerships with leading cell and gene therapy players are most likely to move the needle for OXB,” said James Orsborne, an equity research analyst at Stifel, an investment bank.

In particular, Orsborne highlighted Biomedica’s expanded partnerships with pharma giants Novartis (CH:NVS) and Bristol Myers Squibb (US:BMY) as potential revenue drivers going forward. The company also entered into an agreement with Boston-based Homology Medicines to manufacture viral-vector based vaccines at the start of this year. Biomedica has an 80 per cent stake in the venture, and the acquisition drove its first half operating expenses up while negatively impacting its free cash flow generation.

Ultimately, the Covid sell-off was bound to impact smaller biotechs more than diversified pharmaceutical titans. For now, investors in firms that have been devalued in the latter days of the pandemic must assess whether Covid cash flows are being redirected into more sustainable lines of business. “Clearly, it was impossible to predict how the pandemic was going to play out and how long it would last,” Orsborne said. “In hindsight, the market did get overheated and a sell-off was likely, just nobody knew when.”"

[dominiccummings] 22/9/2022 22:22

Well, whoever is walking it down using the bots will walk it up even faster when the right sort of news is around. I expect that news to be more important if it relates to improvements in the macro economy.

Whilst I agree with the President that we are being pigeonholed as a 'Covid vaccine manufacturer' whilst Covid is over, this is on top of the understandable sentiment against loss making companies (which the bio sector exemplifies) during recessionary times.

Our previous Chairman told the audience at more than one AGM. "Don't expect dividends. This sort of company isn't for widows and orphans. Every time it can raise money, it will. The ambition of a company such as OXB is growth first."

I doubt that a cash raise is likely at current price levels anyway, but demonstrating that the purchase of OXB Solutions can be managed without a cash raise, and settling the outstanding loan, will help sentiment in the meantime.

[gigabit] 22/9/2022 18:57

#3925 - thanks for the correction. I put my hands up as I was looking at an older file and those short positions have since been closed. Not good news for DC I suppose but it is what it is.

If you look at the pre-consolidation equivalent price it is currently at 7.2p in 'old' money. So I suppose it would be a penny share but for the 50:1 consolidation exercise.

It will bounce in due course, but I don't expect it any time soon.

[harry s truman] 22/9/2022 18:21

At least the PR team are busy ;)

[harry s truman] 22/9/2022 17:58

wainwrit,

First of all, todays prize for the longest period ever before posting (Member since: 23 Sep 2003).

Secondly 383 trades today or 380 if you exclude the auctions. Of those 380 then 292 were bots.

I don't think any long term holder would wait this long to get out unless they were now financially embarrassed. It makes no sense to me when the management have just said that they expect to breakeven in H2 and are expecting to make multiple announcements in the remaining weeks before Christmas.

I have been wrong before but there are too many red companies on my watch list and I think this is just a huge transfer of wealth going on at the moment. Once the people buying are satisfied then I expect us to return to the figures posted as targets by the following analysts.

How many RNS declarations on holding have you seen by the major shareholders during this market turmoil?

[wainwrit] 22/9/2022 17:10

The statutory limit for reporting a short position is 0.1%. I Have just downloaded the list of open shorts from
OXB doesn't get a mention. So if 5.75% is currently being shorted then there are an awafult lot of shorters out there. Where did this 5.75% come from?

I fear it may be wrong and what we are actually seeing re the share price is long holders getting out quick. I hope not though.

[dominiccummings] 22/9/2022 16:27

No. Hope that helps.

[dominiccummings] 22/9/2022 16:21

Thanks Gigabit. That sort of figure gives me confidence that a big rise will follow the shorting attack.

[stocktastic] 22/9/2022 15:54

That ejector seat being triggered again?

[gigabit] 22/9/2022 12:21

#3919 It appears that 5.57% of OXB shares are currently shorted. But note that organisations shorting less than 0.1% do not need to declare it so it could be a bit more.

[dominiccummings] 22/9/2022 09:40

I wonder how many shares are out on loan?

[harry s truman] 22/9/2022 09:37

Just for interest here, this morning's trade values so far against type (with ALGO = bot machine trade).

tradeValue tradeType
£1,006 P ALGO
£2,457 P ALGO
£484 P ALGO
£588 P
£97 P
£1,529 P ALGO
£31 P ALGO
£123 P ALGO
£584 P
£123 P ALGO
£1,136 P ALGO
£1,876 P
£1,531 P
£73 P
£324 P ALGO
£4,152 P ALGO
£243 P ALGO
£1,473 P ALGO
£42 P ALGO
£930 P ALGO
£246 P ALGO
£38 P ALGO
£4,966 P
£362 P
£123 P ALGO
£227 P ALGO
£934 P ALGO
£595 P ALGO
£2,474 P ALGO
£954 P ALGO
£107 P ALGO
£1,245 P ALGO
£145 P ALGO
£1,329 P ALGO
£8 P
£2,478 P ALGO
£1,455 P ALGO
£292 P
£23 P ALGO
£173 P ALGO
£601 P ALGO
£2,091 P ALGO
£1,933 P
£1,554 P
£151 P ALGO
£818 P ALGO
£582 P ALGO
£1,002 P ALGO
£814 P ALGO
£1,507 P ALGO
£152 P ALGO
£2,516 P ALGO
£407 P ALGO
£2,529 P ALGO
£383 P
£1,034 P ALGO
£164 P ALGO
£1,658 P ALGO
£24 P
£862 P ALGO
£453 P
£453 P
£1,870 P ALGO
£3,942 P ALGO
£8 P ALGO
£148 P
£485 NLIQ P
£41 P